Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of clinical pharmacology

• Publication date

  2005-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/0091270004270642PMID 15601807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validated assays for human cytochrome P450 activities.

  2004influential reference
• Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• Structure of Human Microsomal Cytochrome P450 2C8

  2004cited by this paper
• The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.

  2004cited by this paper
• Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

  2003cited by this paper
• Drug Interactions of Paclitaxel Metabolism in Human Liver Microsomes

  2003cited by this paper
• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

  2003cited by this paper
• Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

  2003cited by this paper
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

  2003cited by this paper
• Gemfibrozil greatly increases plasma concentrations of cerivastatin

  2002cited by this paper
• CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

  2002cited by this paper
• TRIMETHOPRIM AND SULFAMETHOXAZOLE ARE SELECTIVE INHIBITORS OF CYP 2 C 8 AND CYP 2 C 9 , RESPECTIVELY

  2002cited by this paper
• Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.

  2002cited by this paper
• Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.

  2002cited by this paper
• Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology

  2002cited by this paper
• Current progress on esterases: from molecular structure to function.

  2002cited by this paper
• Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

  2002cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

  2001cited by this paper
• Learning from the cerivastatin experience.

  2001cited by this paper
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001cited by this paper
• Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus

  2001cited by this paper
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

  2001cited by this paper
• Drug-Drug Interactions: Clinical Perspective

  2001cited by this paper
• Drug-Drug Interactions

  2001cited by this paper
• A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor.

  2000cited by this paper
• The xenobiotic inhibitor profile of cytochrome P4502C8.

  2000cited by this paper
• Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver

  2000cited by this paper
• Clinical Pharmacokinetics of Cerivastatin

  2000cited by this paper
• Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.

  1999cited by this paper
• Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

  1999cited by this paper
• Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes.

  1999cited by this paper
• Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.

  1999cited by this paper
• Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans.

  1997cited by this paper
• Pharmacokinetics and bioavailability of montelukast sodium (MK‐0476) in healthy young and elderly volunteers

  1997cited by this paper
• Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.

  1995cited by this paper
• Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

  1992cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Goodman and Gilman's The Pharmacological Basis of Therapeutics

  1986cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• Topical Pharmacology of Imidazole Antifungals

  1976cited by this paper

• Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies

  2025cites this paper
• Deep Learning Models for Predicting Human Cytochrome P450 Inhibition and Induction

  2025cites this paper
• Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans

  2024cites this paper
• Ionic Liquid 1-Octyl-3-Methylimidazolium (M8OI) Is Mono-Oxygenated by CYP3A4 and CYP3A5 in Adult Human Liver

  2024cites this paper
• Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives

  2023cites this paper
• Rising burden of superficial fungal infections in India and the role of Clotrimazole for optimal management

  2023cites this paper
• Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol

  2023cites this paper
• Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling

  2023cites this paper
• Challenges and Opportunities in P450 Research on the Eye

  2023cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions

  2022cites this paper
• Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes

  2022cites this paper
• Drug metabolism and drug transport of the 100 most prescribed oral drugs

  2022cites this paper
• Prospective Prediction of Dapaconazole Clinical Drug–Drug Interactions Using an In Vitro to In Vivo Extrapolation Equation and PBPK Modeling

  2022cites this paper
• Inhibitory effect of 20(S)-protopanaxadiol on cytochrome P450: Potential of its pharmacokinetic interactions in vivo.

  2022cites this paper
• Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension

  2022cites this paper
• An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria

  2022cites this paper
• Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.

  2021cites this paper
• Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

  2021cites this paper
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK (Alpha), South Africa (Beta), and India (Delta)

  2021cites this paper
• Fatty acid oxidation and photoreceptor metabolic needs Thematic Review Series: Seeing 2020: Lipids and Lipid-Soluble Molecules in the Eye

  2021cites this paper
• Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays

  2021cites this paper
• Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders.

  2021cites this paper
• In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods.

  2021cites this paper
• In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-β-D-glucuronide in the Liver

  2021influential citation
• Drug‐Metabolizing Enzymes and Drug Toxicity

  2021cites this paper
• Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.

  2021cites this paper
• Targeting Neurovascular Interaction in Retinal Disorders

  2020cites this paper
• Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes

  2020cites this paper
• Fatty acid oxidation and photoreceptor metabolic needs

  2020cites this paper
• Eicosanoids and Oxidative Stress in Diabetic Retinopathy

  2020cites this paper
• Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry

  2019cites this paper
• The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity

  2019cites this paper
• Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8

  2019cites this paper
• Dyslipidemia in retinal metabolic disorders

  2019cites this paper
• Effect of pterostilbene on in vitro drug metabolizing enzyme activity

  2019cites this paper
• Clinically Significant Drug-Drug Interaction in a Large Antiretroviral Treatment Centre in Lagos, Nigeria.

  2019cites this paper
• Zafirlukast and vincamine ameliorate tamoxifen‐induced oxidative stress and inflammation: Role of the JNK/ERK pathway

  2018cites this paper
• Screening for Biologically Annotated Drugs That Trigger Triacylglycerol Accumulation in the Diatom Phaeodactylum1

  2018cites this paper
• Identification of metabolites of MDR‐1339, an inhibitor of &bgr;‐amyloid protein aggregation, and kinetic characterization of the major metabolites in rats

  2018cites this paper
• Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo

  2018cites this paper
• Thiazolidinediones and their drug interactions involving CYP enzymes

  2018cites this paper
• In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone 
Metabolites of Albendazole, Triclabendazole, Aldicarb, Methiocarb, Montelukast and Ziprasidone

  2018cites this paper
• Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects

  2018cites this paper
• Narrative Review v-3 and v-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases

  2017cites this paper
• Inhibitory Effect of Selaginellins from Selaginella tamariscina (Beauv.) Spring against Cytochrome P450 and Uridine 5′-Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes

  2017cites this paper
• The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.

  2017cites this paper
• Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.

  2017cites this paper
• The role of human CYP2C8 in the metabolizing of montelukast-like compounds: a computational study

  2017cites this paper
• Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect

  2017cites this paper
• Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method.

  2017cites this paper
• ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

  2017cites this paper
• The prenylated phenolic natural product isoglycycoumarin is a highly selective probe for human cytochrome P450 2A6

  2017influential citation
• Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses

  2016influential citation
• Cytochrome P450 Oxidase 2C Inhibition Adds to &ohgr;-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization

  2016cites this paper
• Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis

  2016influential citation
• Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.

  2016cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016influential citation
• Hierarchical mechanistic modelling of clinical pharmacokinetic data

  2016cites this paper
• Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases

  2016cites this paper
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015cites this paper
• Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics

  2015cites this paper
• Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.

  2015cites this paper
• A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives

  2015influential citation
• Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes

  2015cites this paper
• Isolation and Characterization of Phenolic Compounds and Anthocyanins from Murta (Ugni molinae Turcz.) Fruits. Assessment of Antioxidant and Antibacterial Activity

  2015cites this paper
• Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

  2015cites this paper
• Variability in human in vitro enzyme kinetics.

  2014cites this paper
• Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.

  2014cites this paper
• The single‐dose pharmacokinetics of alitretinoin and its metabolites are not significantly altered in patients with cirrhosis

  2014cites this paper
• Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process

  2014cites this paper
• UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL FACULTAD DE ESPECIALIDADES EMPRESARIALES CARRERA DE INGENIERÍA EN ADMINISTRACIÓN DE VENTAS

  2014cites this paper
• Role of rat cytochromes P450 in the oxidation of 17α-ethinylestradiol.

  2014cites this paper
• Identification and mechanistic investigation of clinically important myopathic drug-drug interactions

  2014cites this paper
• Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats

  2014cites this paper
• Role of CYP2C8 in the metabolism of montelukast and imatinib : Studies in vitro, in silico and in humans

  2014influential citation
• Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.

  2014cites this paper
• Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions

  2014cites this paper
• No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

  2014cites this paper
• Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast.

  2014cites this paper
• Stromal and epithelial changes in breast cancer following endocrine treatment

  2014cites this paper
• Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib—a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer

  2014cites this paper
• OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

  2013cites this paper
• Evaluation of the Relationship between Sex, Polymorphisms in CYP2C8 and CYP2C9, and Pharmacokinetics of Angiotensin Receptor Blockers

  2013cites this paper
• Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues

  2013cites this paper
• RSC_IB_C2IB20204B 1..21

  2013cites this paper
• In vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomes

  2013cites this paper
• Evaluation of Food–drug Interaction of Guava Leaf Tea

  2013influential citation
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• Nanocarreadores lipídicos contendo quercetina: desenvolvimento, caracterização físico-química e avaliação biológica in vivo

  2012cites this paper
• The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport.

  2012cites this paper
• Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

  2012cites this paper
• Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.

  2012cites this paper
• Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

  2012cites this paper
• Toward reduction in animal sacrifice for drugs: Molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates

  2012cites this paper
• A Screening Study of Drug–Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel

  2012cites this paper
• 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets.

  2012cites this paper
• Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition.

  2012cites this paper